CytomX Therapeutics (CTMX) Financial Statements

953 Followers

CytomX Therapeutics Financial Overview

CytomX Therapeutics's market cap is currently $903.62M. The company's EPS TTM is $0.01; its P/E ratio is -33.83; CytomX Therapeutics is scheduled to report earnings on April 30, 2026, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Income Statement
Total Revenue	$ 76.20M	$ 138.10M	$ 101.21M	$ 53.16M	$ 37.31M
Gross Profit	$ 76.20M	$ 138.10M	$ 101.21M	$ 53.16M	$ 37.31M
Operating Income	$ -19.56M	$ 25.00M	$ -6.48M	$ -101.33M	$ -116.04M
EBITDA	$ -18.19M	$ 26.76M	$ -4.31M	$ -98.89M	$ -113.34M
Net Income	$ -17.37M	$ 31.87M	$ -569.00K	$ -99.32M	$ -115.87M
Balance Sheet
Cash & Short-Term Investments	$ 137.05M	$ 100.62M	$ 174.51M	$ 193.65M	$ 305.23M
Total Assets	$ 151.57M	$ 120.53M	$ 201.79M	$ 260.89M	$ 339.41M
Total Debt	$ 4.24M	$ 9.38M	$ 13.97M	$ 18.06M	$ 21.67M
Net Debt	$ -8.43M	$ -28.67M	$ -3.20M	$ -175.59M	$ -183.86M
Total Liabilities	$ 52.56M	$ 120.99M	$ 249.24M	$ 346.64M	$ 339.87M
Stockholders' Equity	$ 99.01M	$ -456.00K	$ -47.45M	$ -85.75M	$ -459.00K
Cash Flow
Free Cash Flow	$ -75.81M	$ -86.54M	$ -56.88M	$ -112.53M	$ -120.64M
Operating Cash Flow	$ -75.59M	$ -86.23M	$ -56.03M	$ -110.79M	$ -119.03M
Investing Cash Flow	$ -59.74M	$ 99.70M	$ -150.67M	$ 98.26M	$ 22.49M
Financing Cash Flow	$ 110.45M	$ 7.52M	$ 30.23M	$ 648.00K	$ 110.21M

Currency in USD

CytomX Therapeutics Earnings and Revenue History

Income Statement >

CytomX Therapeutics Debt to Assets

Balance Sheet >

CytomX Therapeutics Cash Flow

Cash Flow >

CytomX Therapeutics Forecast EPS vs Actual EPS

Currently, no data available

Please return soon. This page is being updated.

Earnings >